Phase 1 Safety - Incidence of MAAEs Through 1 Week;Phase 1 Safety - Incidence of MAAEs Through 30 Days;Phase 1 Safety - Incidence of MAAEs Through 6 Months;Phase 1 Safety - Incidence of SAEs Through 1 Week;Phase 1 Safety - Incidence of SAEs Through 30 Days;Phase 1 Safety - Incidence of SAEs Through 6 Months;Phase 1 Safety - Incidence of Solicited Local Reactogenicity AEs;Phase 1 Safety - Incidence of Solicited Systemic Reactogenicity AEs;Phase 1 Safety - Incidence of Unsolicited AEs Through 1 Week;Phase 1 Safety - Incidence of Unsolicited AEs Through 30 Days

Phase 1 Safety - Incidence of MAAEs Through 1 Week;Phase 1 Safety - Incidence of MAAEs Through 30 Days;Phase 1 Safety - Incidence of MAAEs Through 6 Months;Phase 1 Safety - Incidence of SAEs Through 1 Week;Phase 1 Safety - Incidence of SAEs Through 30 Days;Phase 1 Safety - Incidence of SAEs Through 6 Months;Phase 1 Safety - Incidence of Solicited Local Reactogenicity AEs;Phase 1 Safety - Incidence of Solicited Systemic Reactogenicity AEs;Phase 1 Safety - Incidence of Unsolicited AEs Through 1 Week;Phase 1 Safety - Incidence of Unsolicited AEs Through 30 Days

Phase 1 Safety - Incidence of abnormal changes of laboratory safety examinations;Phase 1 Safety - Incidence of local reactogenicity AEs;Phase 1 Safety - Incidence of MAAEs and SAEs through 30 days;Phase 1 Safety - Incidence of MAAEs and SAEs through 6 months;Phase 1 Safety - Incidence of medically-attended MAAEs and SAEs;Phase 1 Safety - Incidence of solicited systemic reactogenicity AEs;Phase 1 Safety - Incidence of unsolicited AEs through 1 week;Phase 1 Safety - Incidence of unsolicited AEs through 30 days;Phase 1 Safety - Vital Sign - Blood Pressure;Phase 1 Safety - Vital Sign - Heart Rate;Phase 1 Safety - Vital Sign - Respiratory Rate;Phase 1 Safety - Vital Sign - Temperature;Phase 2 Cellular Immunogenicity - T cell activity;Phase 2 Humoral Immunogenicity - GMT of neutralizing antibody;Phase 2 Humoral Immunogenicity - GMT of S-specific and N-specific IgG antibodies

Phase 1 Safety - Incidence of abnormal changes of laboratory safety examinations;Phase 1 Safety - Incidence of local reactogenicity AEs;Phase 1 Safety - Incidence of MAAEs and SAEs through 30 days;Phase 1 Safety - Incidence of MAAEs and SAEs through 6 months;Phase 1 Safety - Incidence of medically-attended MAAEs and SAEs;Phase 1 Safety - Incidence of solicited systemic reactogenicity AEs;Phase 1 Safety - Incidence of unsolicited AEs through 1 week;Phase 1 Safety - Incidence of unsolicited AEs through 30 days;Phase 1 Safety - Vital Sign - Blood Pressure;Phase 1 Safety - Vital Sign - Heart Rate;Phase 1 Safety - Vital Sign - Respiratory Rate;Phase 1 Safety - Vital Sign - Temperature;Phase 2 Cellular Immunogenicity - T cell activity;Phase 2 Humoral Immunogenicity - GMT of neutralizing antibody;Phase 2 Humoral Immunogenicity - GMT of S-specific and N-specific IgG antibodies